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Amyotrophic Lateral Sclerosis (ALS) is a fatal, adult-onset progressive degenerative 
motor neuron disease that is characterized by muscle atrophy and weakness due to 
the loss of upper and lower motor neurons. Average survival time for individuals 
diagnosed with the disease is three to five years; currently there is no cure and only 
one drug approved by the Food and Administration (FDA). Scientists have proposed 
various theories in order to solve the mystery which surrounds ALS. One of these 
theories hypothesizes how hyperexcitability and excitotoxicity leads to the death of 
motor neurons. In this study, we will address ways of combatting the effects of 
hyperexcitability as well as excitotoxicity by targeting a specific channel type. The 
channels in question are small conductance calcium activated potassium channels 
(SK channels). We chose to target these channels because they directly affect the 
medium after-hyperpolarization (mAHP) of the cell which controls firing rate. We 
postulate that SK channels are being altered in such a way that cell firing rate has been 
increased, leading to phenotypes associated with the disease such as abnormal 
excitability, mitochondrial dysfunction, axonal loss motor impairment, muscle 
atrophy as well as excitotoxicity, thus leading to the spread of motor neuron death. 
Upon administration with a specific SK channel activator in the form of CyPPA; 
improvements in motor function and survival were found. These improvements 
iv 
 
suggest that SK channels are indeed viable drug targets and specific SK channel 
activators may be treatment options for individuals suffering from ALS.  
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Amyotrophic Lateral Sclerosis  
 
Amyotrophic Lateral Sclerosis (ALS) is a fatal, adult-onset neurodegenerative 
disease that affects upper and lower motor neurons causing weakness, paralysis, 
and eventual death (Bruijn, Miller, & Cleveland, 2004). In ALS, cortical and spinal 
motor neurons (MNs) degenerate progressively (Rowland & Shneider, 2001). 
Survival time for ALS patients is 3-5 years and currently there is no cure (Hirtz et al., 
2007). Patients diagnosed with the illness initially suffer from muscle weakness and 
tremors that later progress to paralysis (Byrne et al., 2011). Roughly 90% of all ALS 
cases are of an unknown etiology and are classified as sporadic (SALS) (Simpson & 
Al-Chalabi, 2006). While the remaining cases are considered familial (FALS) (Gros-
Louis, Gaspar, & Rouleau, 2006). FALS is inherited in a dominant manner and 
approximately 20% of these are linked to mutations of Cu/Zn superoxide dismutase 
type-1 enzyme (SOD1) (Rosen et al., 1993). The clinical similarity between familial 
and sporadic cases of ALS indicates that although etiology may be multifactorial, 
different disease-triggering factors converge on a common pathway of MN death.  
To combat MN death drugs have been administered as potential treatments 
to stave off disease related symptoms. Riluzole is currently the only drug FDA 
approved to treat ALS (Worldwide ALS, 2015). It is known for having many actions 
which include, targeting TTX sensitive Na+ channels, inhibiting kainate and N-
Methyl-D-aspartic acid (NMDA) receptors and activating SK channels (Dimitriadi et 
al., 2013; Gurney et al., 1996). This non-specific drug, only produces modest 
increases in survival of up to 2 – 3 months in ALS patients (Bensimon, Lacomblez, 
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Meininger, & Group, 1994; R. G. Miller et al., 1996; R. Miller, Mitchell, Lyon, & Moore, 
2002) while also producing slight extensions (~10 days) of survival in SOD1 mice 
(Bellingham, 2011; Gurney et al., 1996). Interestingly little to no changes in motor 
function have been reported with treatments of Riluzole (Gurney et al., 1996).  
The lack of available treatments for individuals suffering from ALS makes it 
important for scientists to test various therapeutic avenues with the hopes of 
ameliorating the phenotypes ALS presents. Data compiled from computational 
modeling in our lab predicted a downregulation of SK channel conductance. 
Immunohistochemistry experiments in our lab confirmed this prediction by 
showing a decrease in SK channel cluster area and density in mutant MNs as 
compared to WT. This data suggested to us that SK channel could be a novel drug 
target in ALS that if activated may suppress disease related symptoms. 
Pharmaceutical activation with an SK channel could allow for the reduction of 
glutamate-induced excitotoxicity as well as cell hyperexcitability, allowing the 
preservation of neurons; thereby leading to enhanced motor function and prolonged 
survival in ALS.  
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Hyperexcitability/Excitotoxicity and Motor Neuron Death 
 
Glutamate induced excitotoxicity is the concept of neural degeneration 
caused by the over-stimulation of glutamate receptors (Olney, Mcgeer, & Mcgeer, 
1978). Glutamate excitotoxicity and subsequent MN death has been increasingly 
recognized as an important pathophysiological factor in ALS. In addition, reduced 
expression of the glutamate transporter, excitatory amino acid transporter 2 
(EAAT2), has been reported in the SOD1 mouse model and in the spinal cord of ALS 
patients (Philips & Robberecht, 2011; Rothstein, 1996). Increased expression of 
glutamate receptors permeable to influx of Na+ and Ca2+ ions has been reported on 
MNs in ALS, thus increasing susceptibility to glutamate toxicity (Williams et al., 
1997). Ultimately, an influx of Ca2+ ions through NMDA receptors occurs, resulting 
in increased intracellular Ca2+ concentration and activation of Ca2+-dependent 
pathways that mediate neuronal death (Choi, 1987; Meldrum & Garthwaite, 1990) 
(Figure 1, A & B). It has been suggested that neuronal cell death by excitotoxicity can 
be attributed to either apoptosis or necrosis (Ientile et al., 2001). 
Calcium plays a vital role in the cell signaling pathway which leads to the 
apoptotic cell death of MNs (Figure 2). Calcium is usually free and unbound in the 
synaptic cleft after being released from presynaptic vesicles. Once glutamate has 
bound to the NMDA receptors on the postsynaptic neuron, Ca2+ is free to enter the 
cell (Figure 2A). Once inside the cell Ca2+ enters the endoplasmic reticulum (ER) via 
the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump (Joseph & Hajnóczky, 
2007; Mattson & Chan, 2003). Enhanced translocation of Ca2+ from the ER to the 
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mitochondria results in mitochondrial Ca2+ overload. Initiating the release of 
numerous apoptotic proteins into the cytoplasm, one of which is known as 
cytochrome C (CYT C) (Joseph & Hajnóczky, 2007) (Figure 2B). Coincidently, 
enhanced Ca2+ efflux from the ER can also be promoted by CYT C, by directly 
activating IP3 receptors which allow increased efflux of Ca2+ from the ER (Mattson & 
Chan, 2003). In time mitochondrial Ca2+ overload will induce swelling of the 
mitochondria leading to disturbances and eventual mitochondrial rupture. Once 
ruptured, the release of apoptotic factors enters the cytosol. CYT C together with 
apoptosis protease activating factor 1 (APAF-1), forms “apoptosome” which results 
in the activation of procaspase-9, and in turn activation of effector caspases 
(caspases-3, -6, and -7) ultimately leading to eventual cell death (Pinton, Giorgi, 
Siviero, Zecchini, & Rizzuto, 2008) (Figure 2C). Execution of mitochondria-related 
apoptosis can be connected with mitochondrial dysfunction, increased reactive 
oxygen species (ROS) production, and alterations to Ca2+ homeostasis; all of these 
pathologies are observed in the ALS phenotype which eventually leads to MN 
degeneration (Mattiazzi et al., 2002; Pinton et al., 2008).  
 All voluntary movement relies on lower motor neurons (LMNs), which 
innervate skeletal muscle fibers and act as a link between upper motor neurons 
(UMNs) and muscles (Bear, Connors, & Paradiso, 2007). UMNs originate in the 
motor region of the cerebral cortex; they give rise to descending tracts that 
terminate on interneurons or MNs in cranial nerve motor nuclei or in spinal cord 
gray matter (Fletcher, 2012; Saladin, Sullivan, & Gan, 2015). LMNs are located in 
either the anterior grey column and anterior nerve roots (spinal MNs) (Fletcher, 
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2012). Eisen et al 1992 (Eisen, Kim, & Pant, 1992) suggested that increased 
excitability might be a mechanism causing both UMN and LMN degeneration in ALS 
(Plaitakis & Caroscio, 1987).  
 Excitability may be defined as the “capacity to be activated by or react to a 
stimulus” (“Excitable.,” n.d.). Thus, hyperexcitability means an increased or 
exaggerated response to a stimulus. An example of hyperexcitability in denervated 
skeletal muscle and ALS occurs in the form of fasciculations (Mamede de Carvalho & 
Swash, 2016; Neelands, Herson, Jacobson, Adelman, & Maylie, 2001). Fasciculations 
are brief, spontaneous contractions affecting a small number of muscle fibers, often 
causing a flicker of movement under the skin (Oxford Dictionaries, n.d.). 
Fasciculation and cramp are commonly observed clinical features in ALS and are 
considered to be representative features of LMN hyperexcitability (Mamede De 
Carvalho & Swash, 2013). A hallmark characteristic of the disease, fasciculation 
potentials (FPs) have been shown to precede the disease by many months and the 
presence of FPs is commonly used as a clinical diagnostic feature (M. De Carvalho & 
Swash, 2004; T. M. Li, Alberman, & Swash, 1988). With disease progression, FPs 
become complex and unstable (Mamede de Carvalho & Swash, 2016), and in 2014 
and 2016 Shimizu et al and Bokuda et al concluded that a high frequency of FPs 
correlated with increased disease severity (Bokuda et al., 2016; Shimizu et al., 
2014). It seems that early identification of a hyperexcitable motor system might 
help in the predication of the development of ALS and, may provide a chance to 
make some early ”neuroprotective” intervention prior to disease onset (Mamede de 
Carvalho, 2011). Interestingly, Shibuya et al 2011 suggested that fasciculations in 
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ALS are caused by reduced potassium channel clusters (Shibuya et al., 2011). A 
reduction of these clusters would cause decrease K+ conductance increasing 
excitability. However, increasing K+ conductance by activating channels that directly 
affect the AHP could also allow for the reduction of a hyperexcitable state. 
 There is evidence that hyperexcitability and excitotoxicity play key roles in 
the disease mechanism and Riluzole is used to suppress the effects of both of these 
pathologies (Van Den Bosch, Van Damme, Bogaert, & Robberecht, 2006). However, a 
number of concerns regarding therapeutic effect still remains regarding Riluzole. 
Patients treated with Riluzole only see slight extensions of survival, usually only by 
a few months (2 – 3) and previous studies have shown no improvements in motor 
function in SOD1 mice. (Gurney et al., 1996; Lacomblez, L., Bensimon, G., Meininger, 
V., Leigh, P., & Guillet, 1996; R. Miller et al., 2002). Riluzole has numerous targets, 
most of which are ion channels. This suggests that the disease may be caused by a 
type of channelopathy. If this is the case, discovering affected channel(s) would 
improve our understanding of the disease while also leading to potential 
therapeutic targets. Targeting a channel type which directly affects cell excitability 






Figure 1: Excitotoxicity and Motor Neuron Death 
A. Under normal conditions, the glutamate released by the presynaptic neuron stimulates the 
Ca2+-permeable AMPA receptors present in the postsynaptic motor neuron. This leads to a 
moderate, non-toxic increase of the cytoplasmic Ca2+ concentration (Van Den Bosch et al 2006). B. 
Damage to the EAAT2 transporter can be caused due to the presence of mutant (mt) SOD1. 
Moreover, activated microglial cells can secrete substances that increase the glutamatergic 
stimulation of the postsynaptic neuron. A further increase in these factors leads to an increase in 
the cytoplasmic Ca2+ concentration in the postsynaptic neuron. This leads to the generation of 
toxic reactive oxygen species in the mitochondria. Once the buffering capacity of the 
mitochondria is exceeded, intracellular Ca2+ over-activates Ca2+ dependent enzymes. This 
interferes with normal neuronal functionality leading to neuronal death and ultimately the spread 
of neurodegeneration (Van Den Bosch et al 2006). 
 




Figure 2: Mechanism of the Mitochondrial Apoptotic Pathway 
A. Binding of glutamate to the NMDA receptors and free Ca2+ entering the postsynaptic neuron. B. 
Ca2+ enters the ER and mitochondria. C. Apoptotic pathway and death. 
Adapted from Van Den Bosch et al 2006, 
Joseph et al 2007 & Shi et al 2004 
Postsynaptic Neuron 
Ca2+ 
Mitochondrial Ca2+ Overload 
Apoptotic Stimuli 




Small Conductance Calcium Activated Potassium Channels (SK Channels) 
 
Small conductance calcium activated potassium channels (SK channels) are 
widely expressed in the central nervous system as well as α-MNs (Adelman, Maylie, 
& Sah, 2012; Deardorff et al., 2013). SK channels mainly contribute to the after 
hyperpolarization potential (AHP) following action potentials (APs) and suppress 
firing rate (spike frequency) of neurons (Mendelowitz, 1996). This effect allows for 
a regular firing pattern and a reduction in spontaneous activity preventing 
hyperexcitability. SK channels are so named because they have a small conductance 
of approximately 10–14 pS (Blatz, A. L., & Magleby, 1986). SK channels share the 
same tetrameric architecture with voltage-dependent potassium channels. Each 
subunit is composed of six transmembrane α-helical domains that are denoted S1- 
S6. A loop between the S5 and S6 transmembrane domains forms the potassium ion 
selectivity filter (Cui, Qin, Yu, Bowers, & Zhang, 2014). Most potassium selective 
channels are voltage gated, however SK channels become modified due to their 
response to elevated Ca2+ levels. They are highly sensitive to calcium, being 
activated in the sub-micromolar range (Kohler et al., 1996) The Ca2+ binding protein 
calmodulin (CaM) is constitutively associated with SK channels at the CaM-binding 
domain (CaMBD). The CaMBD is located in the proximal C-terminus of the channel 
subunit (Wissmann et al., 2002). Ca2+ binding to CaM induces conformational 
changes in both CaM and CaMBD that subsequently trigger an opening of the 
channel pore, (Schumacher, Rivard, Ba, & Adelman, 2001) allowing potassium efflux 
(Figure 3). SK channels are activated by elevations in cytosolic Ca2+ from several 
sources which include; voltage dependent N-type calcium (Cav1.3) channels or 
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through permeable agonist-gated ion channels, such as NMDARs and nicotinic 
acetylcholine receptors (nAChrs) (Schutter & Smolen, 1998). 
In many neurons a single AP or bursts of APs are followed by a prolonged 
AHP. (Barrett & Barret, 1967). The AHP has several overlapping components, which 
include the fast, medium and slow AHPs. SK channels have been found to be present 
in most types of neurons, including MNs, and are responsible for the medium-
duration postspike after hyperpolarization (mAHP) (McLarnon, 1995). Potassium 
efflux through SK channels hyperpolarizes the cell, modulating cell excitability (Lam, 
Coleman, Garing, & Wulff, 2013; Wulff & Köhler, 2013). The mAHP activates rapidly 
and decays over several hundred milliseconds. In many cases the mAHP is blocked 
by apamin, which increases excitability and identified that SK channels indeed alter 
cell firing rate. These apamin sensitive SK channels can be found in a wide variety of 
neurons including MNs. The contribution of SK channels to the AHP is due largely to 
their activation by Ca2+ influx via Cav1.3 channels (Edgerton & Reinhart, 2003). In 
LMNs there are two functionally distinct SK channel populations. Specifically, ones 
that mediate the mAHP are activated by Ca2+ influx through N- and P/Q-type 
Ca2+channels (X. Li & Bennett, 2007). It has been suggested that activation of SK 
channels may elicit protection against glutamate-induced excitotoxicity because of 
the hyperpolarizing signal SK channels produce (Benítez et al., 2011; Dolga et al., 
2008).  
While SK channels have not been directly implicated in ALS, there has been 
evidence that they may be a target for study. By modifying the AHP conductance SK 
channels play an important role in regulating MN excitability. Elimination of SK 
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conductance abolishes the mAHP, increasing repetitive firing (X. Li & Bennett, 
2007). Therefore, increasing SK conductance could decrease firing frequency in 
hyperexcitable cells. This signal would allow MNs to have a normalized firing rate, 
reducing spontaneous activity, alleviating metabolic demands and oxidative stress. 
In ALS, protection against these pathologies would likely lead to the survival of MNs, 









Figure 3: SK Channel Mechanism 
A. N-Type Ca2+ channel opens allowing an influx of Ca2+ into the cell. B. Ca2+ binding to CaM 
induces conformational changes in both CaM and CaMBD. C. This induces conformational changes 
in both CaM and CaMBD that triggers an opening of the channel pore allowing K+ efflux. Activation 




Transgenic Mouse Line SOD Mutation  
 
To study ALS in the lab, it is common for animal transgenic lines to be 
utilized. The FUS, TDP-43, C9orf72 and the SOD1 mutations are the four main genes 
which are most commonly tested and each represents a form of FALS (Vajda et al., 
2017). In our behavioral drug studies we will be using one of the SOD1 mutations, 
which are the most studied animal transgenic lines in the field. 
SOD1 mutant lines exhibit a point mutation in the superoxidase dismutase 1 
gene, which were generated by constitutively expressing mutant human SOD1 mini-
genes in mice (Gurney et al., 1994). Mutations in the SOD1 gene are the most studied 
form of inherited ALS, accounting for ∼20% of all the FALS forms (Rosen et al., 
1993). Of all of the SOD1 mutant models, the G1H (high-copy line with 25 copies) 
line of the SOD1-G93A mutant murine strain is one of the most widely characterized 
and studied models of ALS currently available (Turner & Talbot, 2008). Mice 
overexpressing this form of mutant SOD1 develop a phenotype similar to that of ALS 
patients including motor impairment, axonal loss, MN death, muscle atrophy and 
limb weakness (Fischer et al., 2004). This transgenic line is the most aggressive 
form of the disease presenting a phenotype of early disease onset and rapid disease 
progression. Disease onset occurs in 3 months (90 days) and has a duration of only 
1-2 months (125 days); (Chiu et al., 1995). The G93A-H transgenic line, contrasts 
with the low-copy G93A strain (G93A-L) which has a disease onset of 6-8 months 
(170 days), and duration of 2-3 months (225 days); (Gurney, 1997; Quinlan, 
Schuster, Fu, Siddique, & Heckman, 2011). 
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 Early observations of abnormal glutamate metabolism and decreased 
glutamate transport in the brain and spinal cord of ALS patients and SOD1 mice led 
to the hypothesis that the excitatory amino acid neurotransmitter glutamate may be 
involved in the ALS pathogenesis (Plaitakis, 1990; Rothstein, Martin, & Kuncl, 1992). 
Therefore, drugs affecting the glutamatergic system were suggested as therapeutic 
agents to reduce cell firing. The reduction of firing rate of α-MN seems to be 
imperative for sustaining a healthy motor system. This can be accomplished by 





SK Channels in the SOD1 Model 
Quinlan and colleagues reported a decrease in the AHP half-duration  
although no changes were found in the AHP amplitude of their neonatal; postnatal 
day 10 (P10)  SOD1 mutant MNs using a slice preparation (Quinlan, 2011). 
Inhibition of SK channels has been shown as a source of neuromodulation of the 
AHP and has been shown to increase motor neuron firing rate(Herrik et al., 2012). 
AHP modulation has been linked to disease-related changes in the G93A model 
(Casas et al., 2013; Herron & Miles, 2012; Saxena et al., 2013). There is also 
computational evidence that reduction of the AHP may lead to persistent inward 
current facilitation, leading to further increases in cell excitability (Elbasiouny, 
Bennett, & Mushahwar, 2006). A reduction in AHP can cause enhanced firing rates, 
leading to the development of oxidative stress (Lancelot et al 1998) and an 
increased load on mitochondrial metabolism. Increased firing rates also contribute 
to disturbances of the cells ion metabolism (Heath & Shaw, 2002). Measures of the 
AHP (which are mediated partially by the SK) have been demonstrated to be 
significantly decreased in human patients with ALS (Piotrkiewicz & Hausmanowa-
Petrusewicz, 2011). Piotrkiewicz et al 2011 monitored single motor unit potentials 
and found that patients with ALS showed increased accurances of motor unit firing 
and decreased AHP when compared to healthy individuals, thus suggesting an 
increase in excitability. Furthermore, a down regulation of SK (a decrease in SK 
conductance) was predicted in simulations of neonatal mutant SOD1 MNs 
(Elbasiouny laboratory, unpublished data). As a means of confirming this prediction, 
a later study which used immunohistochemistry to stain MNs and SK channels was 
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completed (Dukkipati, 2016). It was concluded that area and density of SK channel 
clusters were also reduced in SOD1-G93A mice. The decrease in these cluster 
properties may have altered channel functionality leading to changes in MN 
excitability.  
Considering that computational modeling predicted a downregulation of SK 
conductance and this prediction was confirmed using immunohistochemistry. It was 
decided that CyPPA, a specific SK channel activator and Riluzole, a non-specific drug 
which also activates SK channels would be administered in our behavioral drug 
studies (Cao, Dreixler, Couey, & Houamed, 2002; Grunnet et al., 2001). We are 
hypothesizing that treatment with an SK channel activator would extend survival 
and improve motor function in the SOD1- G93A mouse model. The significance of 
these studies is that we can investigate whether SK channels are potential drug 
targets. We can also investigate whether the SK channel plays a vital role in the ALS 
disease mechanism and test if drug specificity is importatnt for therapeutic 
efectiveness.  
With a channel type identified it was imperative to determine a proper time 
point for drug treatment. Many labs administer treatments with hopes of improving 
disease progression and survival at late time points, typically during symptom 
onset. Koschnitzky et al 2014 completed similar behavioral testing with Fluoxetine 
(Koschnitzky et al., 2014). Fluoxetine increases synaptic serotonin levels which also 
increases spinal MN excitability. It was reported that chronic treatments with 
Fluoxetine, administered from P70-end stage and P-30-endstage presented no 
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impact on disease progression (Koschnitzky et al., 2014). After finding no changes 
on disease progression a new 7 day dosing paradigm was then chosen at a neonatal 
treatment time point (P5 – P11). This time point was chosen because Amendola and 
Durand et al 2008 showed dendritic changes at this same age in SOD1 mice 
(Amendola & Durand, 2008). Koschnitzky and colleagues used this information and 
administered temporary neonatal drug treatments with Fluoxetine from P5-P11. 
Interestingly, this treatment paradigm produced significant impairments in motor 
behavior and a severe reduction in survival. They concluded that short term 
neonatal interventions can affect ALS disease progression, which supports the idea 







 In these studies we used two drugs which target SK channels. The first drug 
chosen was (N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-
amine) (CyPPA) a specific SK channel activator. CyPPA, is a small (MW: 285), 
trisubstituted pyrimidine that belongs to a completely different compound class 
from that of the prototype IK/SK channel activators 1-EBIO and NS309 (Hougaard et 
al., 2007). CyPPA is a positive modulator of SK but not intermediate conductance 
(IK) channels. It is thought that CyPPA act as an allosteric modulator of SK2/SK3 
channels, which increases their sensitivity to activation by cytosolic Ca2+ (Hougaard 
et al., 2007). 
 The use of CyPPA during in vivo preparations have produced pronounced 
increases in the duration of the mAHP (Herrik et al., 2012). These increases reduced 
neuron firing when compared to controls (Herrik et al., 2012). Moreover, inhibition 
of SK channels by apamin, an SK channel blocker leads to faster firing rates and 
increased instantaneous firing rates (Lorenzon & Foehring, 1992; Schwindt, Spain, 
Foehring, Chubb, & Crill, 1988). Apamin has also been shown to block the postspike 
AHP and abolishes the SK-mediated component of the AHP (Herrik et al., 2012; X. Li 
& Bennett, 2007). In other studies, oral administration of CyPPA has improved 
motor performance in the neurodegenerative disorder, Spinocerebellar ataxia type 
2 (SCA2) and in a model of spinal muscular atrophy (SMA). (Dimitriadi et al., 2013; 
Kasumu et al., 2012). These findings suggest that CyPPA may be a possible 
treatment option for other neurodegenerative disorders such as ALS.  
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 The second drug used in these experiments was Riluzole (2-amino-6-
trifluromethoxy-benzothiazole) which is currently the only FDA approved drug to 
treat ALS (Gurney, Fleck, Himes, & Hall, 1998; Worldwide ALS, 2015). Riluzole was 
initially identified as a paralytic agent (Domino, Unna, & Kerwin, 1952) and was 
found to significantly improve muscle strength and disease progression in ALS 
patients (Bensimon et al., 1994; Lacomblez, L., Bensimon, G., Meininger, V., Leigh, P., 
& Guillet, 1996). Riluzole has a variety of pharmacologic actions, including inhibition 
of glutamate release from presynaptic nerve terminals (Martin, Thompson, & 
Nadler, 1993), modulation of the NMDA ionotropic receptor (Debono, Le Guern, 
Canton, Doble, & Pradier, 1993), stabilization of the voltage-dependent sodium 
channels, (Pratt et al., 1992) and inhibition of the high affinity uptake of λ-
aminobutyric acid (GABA), a major inhibitory neurotransmitter (Mantz, 
Laudenbach, Lecharny, Henzel, & Desmonts, 1994).  
 In 1998 Gurney et al showed that treatment with Riluzole increases survival 
of adult G93A-H mice (Gurney et al., 1998). Gurney et al treated adult animals with 
Riluzole from P42 until death at an optimal dosage of 44mg/kg and saw a 10 day 
increase in survival (Gurney et al., 1998), interestingly no changes in motor function 
were shown in their behavioral drug studies (Gurney et al., 1996). Given that 
Riluzole has numerous targets which also includes SK channels (Cao, Dreixler, 
Couey, & Houamed, 2002; Grunnet et al., 2001), the mechanism of Riluzole 
protection remains unclear (Bellingham, 2011; Kuo, Siddique, Fu, & Heckman, 2005; 
Schuster et al., 2012). However, in 2013 Dimitriadi et al suggested that Riluzole was 
beneficial in two models of SMA and works via SK channels by improving 
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neuromuscular function (Dimitriadi et al., 2013). Considering that Riluzole acts via 
SK channels and has been shown to have some therapeutic effect by reducing 
excitability (Dimitriadi et al., 2013; Kuo et al., 2005). Perhaps treatment with CyPPA, 
a more potent and specific channel activator which modifies excitability by 





A shortening of the α-MN mAHP has been noted directly in a mouse in vitro 
electrophysiological study (Quinlan et al., 2011) and indirectly in a study of human 
muscular electrical activity in ALS patients (Piotrkiewicz & Hausmanowa-
Petrusewicz, 2011). A modeling prediction from Elbasiouny et al suggested that a 
downregulation of SK conductance is present in mutant neonatal SOD1 MNs 
(Elbasiouny lab, unpublished results) and Dukkipati et al confirmed this prediction 
using immunohistochemistry (Dukkipati, 2016).  
 
Specific Aims 
1. Investigate whether the SK Channels is an effective drug target in an ALS 
mouse model. 
2. Investigate whether SK channels play a major role in ALS pathogenesis. 
3. Investigate whether drug specificity can affect therapeutic outcomes. 
 
Hypothesis 
Treatment with a specific SK channel activator would extend survival and 
improve motor function of the SOD1-G93A ALS mouse model. Thus, it is 
hypothesized that treatment with a specific SK channel activator would extend 

















 SOD1-G93A-H male mice were grouped housed in barrier facilities on a 
12:12-h light-dark cycle. Food and water were provided ad libitum. All mice tested 
had a background of B6SJL-Tg (Jackson Laboratories, stock #002726) and were age 
matched littermates. All procedures were approved by the Wright State University 
LACUC. In these types of studies a minimum of twelve animals per group is 
recommended to ensure minimal variability (Scott et al., 2008). We will adhere to 
these guidelines and have at least twelve animals in each treatment group. 
Drugs 
 CyPPA (Sigma-Aldrich, CAT No.5493) was administered via three separate 
dosing paradigms. Treatment of CyPPA was given to neonatal mice from P5 to P20 
(CyPPA P5-P20), adult mice from P90 – P96 (CyPPA P90 7 Day) and a daily dosing 
paradigm starting a P90 and ending at death (P90 Daily study). During the neonatal 
dosing paradigm a 16 day treatment period was chosen because SK channels are 
coupled with N-type Ca2+. Since N-type Ca2+ channels mature around P18 (Inagaki & 
Lee, 2013), we thought overlapping drug administration with channel maturation 
during development would be key for therapeutic effects to become present. For all 
studies using CyPPA drug was administered through once daily injections (14mg/kg 
body weight, Intraperitoneal (IP)) or vehicle control (11% DMSO and saline – 16 
Day treatment of  CyPPA at P5 and 7 Day treatment of CyPPA at P90; 11% DMSO, 
5% Kolliphore and Saline – Daily CyPPA treatment at P90) injections. During 
preliminary testing it was found that CyPPA resulted in healthy animals not 
completing the rotarod protocol 30 minutes after dosing. Animals receiving the drug 
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became lethargic and motor function was significantly reduced as they fell off the 
rotarod prematurely. These changes were present up to an hour after injection. 
However, during experimentation drug was administered after behavioral testing to 
avoid any motor performance changes caused by the drug. 
 
 Riluzole (MP Biomedicals, LLC, CAT No. 193713) was administered to 
neonatal mice from P5 – P20 (Riluzole P5-P20), Drug was administered through 
once daily injections (22mg/kg body weight IP) or vehicle control (0.1 Normal HCl, 
diluted in water (DDI)) injections. Riluzole concentration was determined by 
halving the optimal dosage reported in literature since higher dosages of 44mg/kg 











EC50 = 6µM 
Target: Activates KCA2.3, Inhibits 
NaV Channels 
Half Life: Unknown 
 





EC50 = 12µM 
Targets: KCA2.3, TTX Sensitive Na+ 
channels, Inhibits kainate and 
NMDA receptors, BK Channels 
Half Life: 12 Hours 
FDA Approved 
 
- Grant et al 2010 




Behavioral Studies: Protocol and Criteria 
 Behavior studies were performed every other day by individuals blinded to 
genotype and drug condition. Rotarod testing and data collection started at P85 for 
each drug study. Rotarod testing did not start at an earlier age because SOD and WT 
mice show no differences in motor ability until symptoms become present, typically 
around P90. Weight, motor function, end stage, first failure and final failure were 
monitored for all mice. 
 Animals received a period of 4 consecutive days of training on rotarod 
testing paradigm. The training period started at P72. During testing and training 
animals would run on the rotarod for a total of 240seconds. The rotarod was set at 
5rpm for the first 30s, then increased to 10rpm to complete the first minute. The 
rotarod then increased to 15rpm for another 30s and increased to 20rpm for a full 
minute. To finish testing, the rotarod was set at its maximum rotation speed of 25 
rpm for 90 seconds (Table 2). The fall time was recorded via photo beam break on 
the rotarod device (AccuRotor Multi-Animal Rotarod. Omnitech Electronics, Inc 
(Figure 4)). Mice ran three times with at least a five minute break between runs. The 
maximum time from each of the three trials was recorded to determine motor 
function. Maximum time spent on the rotarod was used to prevent daily motor 
performance variance. The age at which mice failed to complete the entire protocol 
(240s) for each of the three trials was recorded; this was considered First failure. 
Final failure was recorded when the animals failed to stay on the rotarod for <12s 
for each of the three trials. Final failure was representative of the animal completing 
<5% of the rotarod protocol and severe motor deficits being present (Figure 5).  
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Rate of Motor Function Loss was used to determine slope of rotarod decline. 
A ten percent drop from the baseline was used to ensure motor decline was present. 
The lower limit of the regression test was determined when animals reached an 
average of ten percent completion (Figure 5). This point was chosen due to the rapid 
disease progression seen in the model. We wanted to ensure our slope was a good 
representation of overall motor function. 
Survival was determined when animals failed the righting reflex test. If they 






Table 2: Rotarod Protocol 
Figure 4: Rotarod 
AccuRotor – Multi Animal Rotarod, Omnitech Electronics, Inc 
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Figure 5: Assessment Criteria 
First failure, time point when animals no longer fully complete the rotarod protocol. Rate of 
Motor Function Loss, Slope and linear fit of rotatod line. To determine slope, a baseline for motor 
function was determined. A ten percent drop from the baseline was instituted to ensure motor 
function decline was present. The lower limit of the regression test was determined when animals 
being tested reached an average of ten percent completion. Ten percent completion is equivalent 
to 24 seconds of time spent on the rotarod. This point was chosen due to the fact that many 
animals drop out of the study because of rapid disease progression. Also, we wanted to ensure 
our slope was a good representation of overall motor function. Final failure was recorded when 
animals failed to stay on the rotarod for <12s for each of the three trials. Final failure was 
representative of the animal completing <5% of the rotarod protocol and severe motor deficits 
being present. Survival was determined when animals failed the righting reflex test. At this point 





 The Kaplan Meier Log Rank survival test was used to analyze final failure and 
overall Survival of the animals. The final failure time point is indicative of severe 
gross motor deficits and a lack of motor control. Survival represents the age when 






 Values are represented as mean ± standard error of the mean. Data, including 
Kaplan Meier survival analysis was analyzed using Statistica 12. Student’s t-test 
were used to analyze differences between first failure, final failure, survival and 
every day the animals ran. All data had normal distributions and equal variance. 
Kaplan Meier survival analysis was used to determine probability of survival for 
motor function and overall survival. The Mann-Whitney U test a nonparametric 
analysis was also used to analyze motor function data. Figures were made with 




























Study 1 - 16 Day Treatment of CyPPA starting at P5 – P20  
Analysis of motor function was completed as described (Figure 6), n for the 
animals receiving CyPPA was 12 and n for the animals receiving the vehicle control 
animals was 13. It was found that animals receiving CyPPA presented no differences 
when testing first failure using a student’s t-test (p = 0.99). First failure for both the 
treatment and the vehicle control groups occurred at P111. However, significant 
differences were found when testing motor function. Analysis of motor function was 
completed using a student’s t-test by testing each day the animals ran. Animals 
receiving CyPPA showed sustained motor function as the disease progressed. 
Starting at P123 – P128 significant differences were found using a student’s t-test 
(P123 - P128: p ≤ 0.0264). Analysis of the Mann-Whitney U test also showed 
significant improvements in motor function between the treatment and control 
vehicle groups from P125 – P128 (p ≤ 0.019). Overall, animals receiving CyPPA had 
significant improvements in motor function (Figure 6).  
To assess motor function, a regression test was utilized to measure the slope 
of motor function decline (Figure 7). Comparison of the SOD-treated vs. the SOD-
Control of the Regression test showed significant differences between the slopes for 
CyPPA and the Vehicle Control. Slope for animals receiving CyPPA was -0.0211, R2 = 
0.85, while the slope for the Vehicle Control animals was -0.0349, R2 = 0.74 (p = 
0.007).  
As the study progressed, animal performance continued to drop. The next 
analysis completed tested final failure (Figure 8). Final failure is the age at which the 
animals stopped running on the rotarod and the presence of gross motor deficits 
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and a lack of motor control is very evident. Animals receiving CyPPA showed a 
significant 7% increase in final failure using a student’s t-test (p = 0.03). Average 
final failure for animals receiving CyPPA occurred at P128, while animals receiving 
the vehicle control occurred at P120.   
Final failure tracks “survival” of motor function and indicates when animals 
lose their ability to balance and coordinate themselves on the rotarod (Figure 9). 
Some labs use a functional time point like final failure as their “survival” criteria 
because they believe it may be a more sensitive gauge (Lutz et al 2009). This 
analysis in the form of a Kaplan-Meier curve shows the percentage of animals 
running over time. Significant differences were found using the Cox’s proportional 
F-Test (p = 0.03), indicating that animals receiving CyPPA retain motor function 
longer as the disease advances. 
In the latter stages of the study, disease progression is quite rapid and many 
animals succumb to the illness (Figure 10). The survival analysis is then completed 
on the animals. Survival is determined when animals fail the righting reflex test 
within a 30 second period. On average animals receiving CyPPA showed a significant 
8% increase in survival using a student’s t-test (p = 0.0063). On average animals 
receiving CyPPA lived 136 days while animals receiving the vehicle control lived 
126 days (a 10 day extension in survival).  
A Kaplan-Meier curve was generated using the survival data and showed 
significant differences for survival between the two groups (Figure 11). Significant 
differences were found using a Cox’s Proportional F-Test (p = 0.007). The oldest 
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animal receiving CyPPA survived for 152 days which was nearly 20 days longer than 
the oldest Vehicle Control animal.  
Study 1 Conclusions 
Significant improvements in motor function and survival were found, 
suggesting a slower disease progression. Animals receiving the 16 day treatment of 
CyPPA presented extended motor function in the latter stages of the disease and an 
increased likelihood that motor function would persist based on the final failure 
analysis using the Kaplan Meier curve. Survival was also improved in the animals 
receiving CyPPA, this 10 day increase equated to nearly an 8% change overall.  
These results show that SK channels could be a potential drug target and 
CyPPA may have therapeutic properties. These results also suggest that CyPPA is a 
potential treatment for SOD1 mutant mice. To further assess its effects, we 






Figure 6: Motor Function – 16 Day Treatment of CyPPA Starting at P5 – P20 
Graph showing average rotarod completion for animals in both treatment groups. Diamonds 
represent average first failure for each group being dosed. Average first failure for the animals 
receiving the vehicle control and CyPPA occurred at P111. No significant differences were present 
testing first failure. Motor function for animals receiving CyPPA was significantly different from 
P123 – P128 using the student’s t-test and from P125 – 128 using the Mann-Whitney U test. 









Rate of Motor Function Loss 
Figure 7: Rate of Motor Function Loss – 16 Day Treatment of CyPPA starting at P5 – P20 
Slope for animals receiving CyPPA was -0.0211 while animals receiving the vehicle control was -
0.0349. Using a regression test we determined that motor function decline was significantly 
different between the two groups, p-value 0.007. Vehicle Control n = 13, CyPPA n =12; Data is 








Figure 8: Final Failure – 16 Day Treatment of CyPPA starting at P5 – P20 
Animals receiving CyPPA increased average final failure by 7%. Final Failure was significant when 






































Final Failure (Kaplan-Meier) 
Figure 9: Final Failure (Kaplan Meier) – 16 Day Treatment of CyPPA starting at P5 – P20 
Animals receiving CyPPA showed significant survival improvements testing motor function using 




Figure 10: Survival – 16 Day Treatment of CyPPA starting at P5 – P20 
Animals receiving treatment of CyPPA lived 10 days longer on average. Which equated to a 
significant 8% increase (p = 0.006). Animal’s receiving CyPPA lived 136 days while animals 
receiving the vehicle control lived 126 days on average. Vehicle Control n = 13, CyPPA n =12; Data 





































Figure 11: Survival (Kaplan-Meier) – 16 Day Treatment of CyPPA starting at P5 – P20 
Animals receiving CyPPA showed significant extension in survival using Cox’s proportional F-Test, 
p-value 0.007. The oldest CyPPA animal lived 152 days, nearly 20 days longer than the oldest 





Study 2 - 16 Day Treatment of Riluzole starting at P5 – P20 
Riluzole was administered via once daily intraperitoneal injections at 
concentration of 22 mg/kg. A concentration of 22 mg/kg was preferred over the 
optimal dosage (44 mg/kg) reported in literature because when tested higher 
concentrations lead to the death of the neonatal mice. The n for animals receiving 
Riluzole and the vehicle control was 12. 
Animals receiving Riluzole showed no significant differences in the first 
failure analysis which was completed using a student’s t-test (p = 0.19). Average 
first failure for animals receiving Riluzole occurred at P93 while animals receiving 
the vehicle control occurred at P88 (Figure 12). Analysis of motor function was 
completed by using a student’s t-test. Unfortunately, no differences were found 
testing motor function.  
A regression test was used to analyze the slope of motor function (Figure 13). 
Analysis of the regression test showed no significant differences between the two 
groups (p = 0.29). Slope for animals receiving Riluzole was -0.0144, R2 = 0.82, 
whereas the slope for the animals receiving the vehicle control was -0.0183, R2 = 
0.89.  
The next analysis completed tested final failure (Figure 14). Again, no 
significant differences were found between the two groups (p = 0.45). Average final 
failure for the animals receiving Riluzole occurred at P121 while final failure for 
animals receiving the vehicle control occurred at P119. Upon completion of the final 
failure analysis, Kaplan-Meier curves were also analyzed for the final failure criteria 
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(Figure 15). No significant differences were found when analyzing the Cox’s 
proportional F-Test (p = 0.34). 
Animals receiving Riluzole showed no changes in survival when assessing 
means using a student’s t-test (p = 0.99). Survival for both the treatment and the 
vehicle control groups occurred at P131 (Figure 16). A Kaplan-Meier curve was 
generated and showed no significant differences for survival between the two 
groups by using the Cox’s proportional F-Test (p = 0.37) (Figure 17). 
Study 2 Conclusions 
Riluzole administration showed no changes in either motor function or 
survival. These results as well as the results from the preceding CyPPA study 
suggest that drugs with specific SK-channel activation properties may have greater 
therapeutic effects than non-specific drugs. 
These short term neonatal studies were very beneficial for studying disease 
mechanisms and pathogenesis. Interestingly, the major takeaways from these 
neonatal studies is that SK channels seem to play a role in the disease mechanism 
and that activation of SK channels may produce therapeutic effects. Given that 
clinical drug treatment starts after ALS diagnosis, we then tested administration of 





Figure 12: Motor Function – 16 Day Treatment of Riluzole starting at P5 – P20 
Diamonds represent average first failure for each group being dosed. Average first failure for the 
animals receiving the vehicle control occurred at P88 and Riluzole occurred at P93. No significant 
differences were present testing first failure or motor function. Vehicle Control n = 12, Riluzole n 






Rate of Motor Function Loss 
Figure 13: Rate of Motor Function Loss – 16 Day Treatment of Riluzole starting at P5 – P20 
Slope for animals receiving Riluzole was -0.0144 while animals receiving the vehicle control was -
0.0186. Using a regression test we determined that motor function decline was not significantly 






Figure 14: Final Failure – 16 Day Treatment of Riluzole starting at P5 – P20 
Animals receiving Riluzole treatment had no change in average final failure. Vehicle Control n = 
































Final Failure (Kaplan-Meier) 
Figure 15: Final Failure (Kaplan-Meier) – 16 Day Treatment of Riluzole starting at P5 – P20 
Animals receiving Riluzole showed no changes in motor function using Cox’s proportional F-Test. 





Figure 16: Survival: 16 Day Treatment of Riluzole starting at P5 – P20 
Animals receiving Riluzole and the vehicle control presented no changes, Riluzole and Vehicle 





































Figure 17: Survival (Kaplan-Meier) 16 Day Treatment of Riluzole starting at P5 – P20 
Animals receiving Riluzole showed no changes in survival using Cox’s proportional F-Test. Vehicle 

















Study 3 - Daily Treatment of CyPPA Starting at P90 – Death   
CyPPA was administered via once daily intraperitoneal injections at 
concentration of 14 mg/kg. We decided on this concentration because of the 
therapeutic effects observed from the previous study (16 Day Treatment of CyPPA 
at P5 – P20) which used the same concentration and we wanted our drug 
concentration to remain consistent throughout the studies. The n for animals 
receiving CyPPA was 13 and n for animals receiving the vehicle control was 14. 
Animals receiving daily treatments of CyPPA presented no significant 
differences in the first failure analysis which was completed using a student’s T-test 
(p = 0.09). Average first failure for animals receiving daily treatments of CyPPA 
occurred at P91 while animals receiving the vehicle control occurred at P87. 
Analysis of motor function was completed by using a student’s T-test (Figure 18). 
No differences were found testing motor function.  
Slope for animals receiving daily treatments of CyPPA was -0.0211, R2 = 0.92. 
Slope for animals receiving the vehicle control was -0.0172, R2 = 0.87. Analysis of 
the regression test again showed no significant changes (p = 0.158) (Figure 19). 
The next criteria analyzed tested final failure or the time in which of gross 
motor deficits and a lack of motor control become present (Figure 20). Final failure 
was not significant between the two groups using a student’s t-test (p = 0.19). 
Average final failure for animals receiving daily treatments of CyPPA occurred at 
P123 while animals receiving the vehicle control occurred at P127. To complement 
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the final failure t-test, Kaplan-Meier survival curves were created (Figure 21). No 
significant differences were found using the Cox’s proportional F-Test (p = 0.9). 
In the later stages of the study, disease progression is quite rapid and many 
animals succumb to the disease (Figure 22). Survival analysis using the student’s t-
test (p = 0.23) and the Kaplan-Meier (p = 0.23) analysis showed no differences 
between the two groups (Figure 23).  
Study 3 Conclusions 
Results from the third study did not show beneficial effects that were present 
in the 16 day CyPPA neonatal study. We hypothesized that treatment with CyPPA 
during symptom onset would produce some therapeutic effect. Given that daily 
administration of SK-channel activators reduce MN firing frequency, daily 
administration could mask the potential beneficial effects of motor function. We 
therefore decided to test short-term administration of CyPPA at symptom onset 




Figure 18: Motor Function – Daily Treatment of CyPPA starting at P90 - Death 
Diamonds represent average first failure for each group being tested. Average first failure for the 
animals receiving the vehicle control occurred at P87 and CyPPA occurred at P91. No significant 
differences were present testing first failure or motor function. Vehicle Control n = 14, CyPPA n 






Rate of Motor Function Loss 
Figure 19: Rate of Motor Function Loss – Daily Treatment of CyPPA starting at P90 - Death 
Slope for animals receiving CyPPA was -0.0211 while animals receiving the vehicle control was -
0.0172. Using a regression test we determined that motor function decline was not different. 






Figure 20: Final Failure – Daily Treatment of CyPPA starting at P90 – Death 
Animals receiving CyPPA had no change in average final failure. Vehicle Control n = 14, CyPPA n 
































Final Failure (Kaplan-Meier) 
Figure 21: Final Failure (Kaplan-Meier) – 16 Day Treatment of CyPPA starting at P90 – Death  
Kaplan-Meier curve showing percent of animals still running on the rotarod. Animals receiving 
CyPPA showed no changes in motor function using Cox’s proportional F-Test. Vehicle Control n = 





Figure 22: Survival – Daily Treatment of CyPPA starting at P90 – Death  
Animals receiving CyPPA and the vehicle control presented no changes in Survival. On average 
animals receiving CyPPA lived for 130 days and Vehicle Control animals lived 134 days. Vehicle 




































Figure 23: Survival (Kaplan-Meier) - Daily Treatment of CyPPA  tarting at P90 – Death  
Kaplan-Meier curve showing percent of animal’s surviving. Animals receiving CyPPA showed no 
changes in survival using Cox’s proportional F-Test. Vehicle Control n = 14, CyPPA n =13; Data is 




Study 4 - 7 Day Treatment of CyPPA starting at P90 – P96 
CyPPA was administered via once daily intraperitoneal injections at 
concentration of 14 mg/kg. We decided on this concentration because of the 
therapeutic effects observed from a previous study (16 Day Treatment of CyPPA at 
P5 – P20) which used the same concentration and we wanted our drug 
concentration to remain consistent throughout each of the studies. The n for 
animals receiving CyPPA was 14 and n for animals receiving the vehicle control was 
14.  
Animals receiving short term treatments of CyPPA showed no significant 
differences in first failure (p = 0.06). Average first failure for animals receiving the 
temporary treatment of CyPPA occurred at P101 (Figure 24). Average first failure 
for animal’s receiving the vehicle control occurred at P93. To our excitement, we 
observed several time points along the motor function graph with significant 
improvements. Animals receiving CyPPA showed sustained motor function as the 
disease progressed. Significant differences were found using a student’s t-test and 
occurred from P92 – P105 and P112 – P119 (P92 – P105, p ≤ 0.05; P112 – P119, p ≤ 
0.03). Analysis of the Mann-Whitney U test also showed significant improvements in 
motor function between the treatment and control vehicle groups from P94 (p ≤ 
0.032), P97 - P100 (p ≤ 0.027), P102 - P103 (p ≤ 0.014), and P114 - P118 (p ≤ 
0.022). 
After finding differences between each day the animals received CyPPA. A 
regression test was used to analyze slope of motor function (Figure 25). Analysis of 
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the regression test showed significant differences between the slopes for the 
temporary treatments of CyPPA and the vehicle control. Slope for the animals 
receiving CyPPA was -0.0207, R2 = 0.92, while vehicle control animals had a slope of 
-0.0263, R2 = 0.92 (p = 0.029). 
The next analysis completed tested final failure (Figure 26). The 
improvements in motor function and rate of motor function loss suggested that the 
final failure criteria may also be significant. Final failure for the animals receiving 
CyPPA occurred at P126 while animals receiving the vehicle control occurred at 
P119. Unfortunately, this 5% increase did not to reach significance (p = 0.06). 
However, generation of the Kaplan-Meier curve did show significant differences 
amongst the percentages of animals running over time (Figure 27). Significant 
differences were found using the Cox’s proportional F-Test (p = 0.03). This 
suggested that animals receiving temporary CyPPA treatments maintain motor 
function as the disease progresses and have a higher probability of motor function 
enduring during the latter stages of the disease. 
Unlike the first study, this final study using CyPPA did not extend survival in 
the SOD1 mutants (Figure 28). On average animals treated with CyPPA lived 135 
days while vehicle control animals lived 129 days (p = 0.25). The Kaplan-Meier 
curve also showed no significant differences for survival between the two groups (p 
= 0.06) (Figure 29). It is interesting to note that in this study we had an animal who 
survived the longest out of any study. This animal lived for 162 days which was 
nearly 20 days longer than the oldest vehicle control animal.  
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Clinically Relevant Conclusions 
Chronic treatments of CyPPA had no therapeutic effect. This lack of beneficial 
effects might have occurred because CyPPA does present some acute motor effects 
after administration. In a preliminary study, it was found that thirty minutes after 
drug administration animals injected with CyPPA would become lethargic and 
motor function was significantly reduced. For all of the clinically relevant studies, 
animals were given drug after behavioral testing to avoid any changes to motor 
output and prevent variances in the data. It is likely that the drug did not directly 
affect motor performance during testing. However, continuous dosing with CyPPA 
during the daily treatment study, potentially kept the animals in a poor state, thus 
producing no therapeutic effects. 
In contrast, short term treatments with the same drug produced significant 
improvements in motor function though survival was unchanged. In the latter 
stages of the disease, motor function was sustained in the animals receiving the 
treatment and they had a higher probability of retaining their motor function later 
in the disease. This suggests that CyPPA is having some therapeutic effect on the 





Figure 24: Motor Function – 7 Day Treatment of CyPPA starting at P90 – P96 
Diamonds represent average first failure for each group being dosed. Average first failure for the 
animals receiving the vehicle control was 93 days while CyPPA occurred at P101. No significant 
differences were present testing first failure, though the p-value was 0.06. Motor function for 
animals receiving CyPPA was significantly different from P92 – P105 and P112 – P119usign the 
student’s t-test.The -Whitney U test also showed significant improvements in motor function 
between the treatment and control vehicle groups from P94 (p ≤ 0.032), P97 - P100 (p ≤ 0.027), 
P102 - P103 (p ≤ 0.014), and P114 - P118 (p ≤ 0.022). Significance was determined when p-value 







Figure 25: Rate of Motor Function Loss – 7 Day Treatment of CyPPA starting at P90 – P96 
Slope for animals receiving CyPPA was -0.0207 while animals receiving the vehicle control was -
0.0263. Using a regression test we determined that motor function decline was significantly 
different between the two groups, p-value was 0.029. Vehicle Control n = 14, CyPPA n =14; Data is 
Mean ± S.E. 





Figure 26: Final Failure – 7 Day Treatment of CyPPA starting at P90 – P96 
Animals receiving CyPPA treatment increased average final failure by 5%. Average final failure for 
the animals receiving the vehicle control was 119 days while CyPPA occurred at P126. No 
significant differences were present testing final failure. Vehicle Control n = 14, CyPPA n =14;  Data 
































Final Failure (Kaplan-Meier) 
Figure 27: Final Failure –7 Day Treatment of CyPPA starting at P90 – P96 
Animals receiving CyPPA showed significant improvements in motor function by staying on the 
rotarod for an extended number of days. Significant differences were found using Cox’s 






Figure 28: Survival – 7 Day treatment of CyPPA starting at P90 – P96 
Animals receiving CyPPA treatment increased survival by 4%. Average survival for the animals 
receiving the vehicle control was 130 days while CyPPA occurred at P134. No significant 

































Figure 29: Survival (Kaplan-Meier) – 7 Day Treatment of CyPPA starting at P90 - P96 
Animals receiving CyPPA showed no significant improvements in survival using Cox’s proportional 
F-Test (p = 0.06). The oldest CyPPA animal lived 162 days (best of all studies), 20 days longer than 





Table 3: Comparison of All Drug Studies 
Table depicting all motor and survival criteria for each study completed. * denotes significance and p-values < 0.05. 



















 To date the underlying mechanism which initiates MN death in ALS is still 
unknown. However, there is evidence that hyperexcitability and excitotoxicity play a 
key role in the disease mechanism. Previous studies from our lab used 
computational modeling as well as immunohistochemistry to test specific channel 
types. Our modeling predicted that SK channels become downregulated and 
immunohistochemistry showed a decrease in SK cluster density and area in the 
SOD1-G93A mutant (Elbasiouny et al, unpublished and Dukkipati, 2016). It is well 
known that SK channels mediate the mAHP regulating cell excitability (Lam et al., 
2013). In the disease, it could be possible that a decrease in these channel types may 
lead to increased cell firing, hyperexcitability, Ca2+ overload and eventual cell death 
due to excitotoxicity. In our studies, drug administration with short term 16 day 
neonatal (P5 – P20) drug interventions with CyPPA produced significant 
improvements in both motor function and survival. While, short term 7 day 
treatments with CyPPA during symptom onset (P90 – P96) also produced significant 
improvements in motor function. 
Our first study which administered CyPPA at neonatal time point (P5-P20) 
showed significant improvements in motor function and survival. Animals receiving 
the treatment of CyPPA had 5 days where motor function was significantly different 
(Figure 6,Table 3). CyPPA also produced a lower slope compared to its vehicle 
control, suggesting a reduced rate of motor function loss (Figure 7). Both analyses of 
final failure and the survival criteria produced significant differences in the favor of 
CyPPA (Figure 8,Figure 9,Figure 10,Figure 11). In support of our findings, a study 
from 2008 suggested that SK activation by either NS309 or CyPPA may have 
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neuroprotective function as they provided protection against glutamate-induced 
excitotoxicity in primary cortical neurons (Dolga et al., 2008). Our data and this 
information suggests that activation of SK channels by CyPPA may reduce the effects 
of excitotoxicity, alleviating symptoms associated with the disease, thus leading to 
the improvements we have reported.  
CyPPA also produced significant motor function improvements during the 
clinically relevant time point, though these results were limited to the short term (7-
Day) treatment. Overall, chronic long term treatments showed no changes in motor 
function or survival. We think this phenomenon was observed because CyPPA has 
acute motor effects, which significantly impairs motor output after injection. Since 
CyPPA has been shown to increase mAHPs which result in a reduction of cell firing 
rate. Continuous administration of CyPPA and the subsequent reduction of MN firing 
likely left animals in a weak state. Animals kept in this state might have become 
more vulnerable to disease changes, thus hampering any therapeutic effect of the 
drug. On the other hand, short term treatments showed significant improvements. 
Motor function and rate of motor function loss were all improved compared to the 
vehicle control and the daily studies (Figure 18Figure 19Figure 24 ,Figure 25 and 
Table 3). Our 7 day treatments also produced significant improvements in the final 
failure Kaplan-Meier analysis (Figure 9). Unfortunately, most of the other analysis 
criteria from the 7 day study produced no significant differences. First failure, final 
failure, and the survival (Kaplan-Meier) analysis all presented p-values of 0.06. It is 
interesting that motor function was improved in the short term treatment even 
though the long term treatment presented no changes. The improvement from the 
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short term treatments suggests that CyPPA may induce functional plasticity. The 
short term 7 day treatments of CyPPA may have allowed for a metabolic break, 
giving the MNs a chance to recover from excitotoxicity, Ca2+ overload, increased 
excitability, causing them rejuvenate. These changes could have harbored a 
protective therapeutic effect on MNs as wells SK channels, preserving motor 
function. Protection of these channels might have led to the normalization of APs to 
a state which is more reminiscent of the pre-symptomatic state. A return to this 
state would have allowed surviving MNs to function normally, staving off disease 
related symptoms, thus producing the significant improvements in motor function. 
This plasticity may have allowed MNs to adapt to the drug effects created by CyPPA, 
producing the therapeutic effects we observed. Conversely, it is also possible that 
continuous drug administration with CyPPA from the daily study caused numerous 
health issues to these mice. It is unknown what actions CyPPA has on the liver, 
respiratory system and cardiovascular systems and so daily interventions with this 
drug might have caused the lack of change in motor function or survival 
The most significant results from this project were the 16 day treatment of 
CyPPA at P5 and the 7 day treatment with CyPPA at P90. When we compared our 
results from these studies we did find some similarities. Motor function and rate of 
motor function loss were both improved (Figure 6,Figure 7,Figure 8Figure 24,Figure 
25, Figure 27 and Table 3) again suggesting that SK channels and treatment with 
CyPPA are suited for protecting against excitotoxic injury (Benítez et al., 2011). 
Unlike the neonatal study, no improvements in survival were observed during the 
clinically relevant time point. During development there are a plethora of MN’s. If 
74 
 
CyPPA has therapeutic properties it is likely that these MNs become more robust 
with treatment during development and end up less affected by disease changes. 
Conversely, treatment with CyPPA during symptom onset starts long after MN death 
has begun. With a limited number of MNs left during the clinically relevant time 
point, the beneficial effects of CyPPA might have been diminished leading to 
improvements in motor function but no changes in survival.  
When we compated CyPPA with Riluzole we saw that drug administration 
with Riluzole presented no effects on motor function or survival in our neonatal 
studies. Interestingly, previous literature has shown significant increases in survival 
when adult G93A-H mutants are treated with Riluzole (Gurney et al., 1998). There 
are vast differences in the Gurney study compared to our study. Gurney et al treated 
adult animals with Riluzole from P42 until death at a concentration of 44mg/kg 
where as our study treated neonatal animals from P5-P20 at a concentration of 
22mg/kg. Neonatal animals given a dosage of 44mg/kg and 33mg/kg ended dying 
from these high concentrations and so a lower concentration of Riluzole was used in 
our studies. The lack of improvements in motor function and survival demonstrates 
that neonatal interventions with Riluzole are not therapeutic and that drug 
treatment with a specific channel activator may be more beneficial than treatment 
with a non-specific drug. Riluzole targets numerous channel types along with SK 
channels (Cao et al., 2002). However, Pedarzani et al 2005 showed that CyPPA is far 
more potent than Riluzole when activating SK channels (Pedarzani et al., 2005). This 
information along with our data, which shows improvements in both motor function 
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and survival by CyPPA, suggests that activation by specific drug therapies can be 
more beneficial than activation by non-specific drugs. 
Completion of these studies suggests that CyPPA and SK channels may have 
therapeutic properties. These changes could have lead to the improvements in 
motor function and survival. Beneficial effects produced by CyPPA may have also 
occurred due to an increased number of SK channels, increased SK expression or 
conductance through the channels. These increases could reduce MN firing rate and 
mAHP, reducing the effects of hyperexcitability and excitotoxicity. The reduction of 
these pathologies in G93A- H mutants may have led to the protection of MNs 
thereby improving motor function as well as survival in some of our studies. In 
support of our findings, previous studies have shown that SK channel activation by 
CyPPA could be considered as a therapy for glutamate-induced excitotoxicity 
(Benítez et al., 2011; Dolga et al., 2008) which would also ameliorate disease related 
symptoms. Given that behavioral testing was completed for these studies 
determining the preservation of MNs is difficult. It is possible that treatment with 
CyPPA during development could strengthen the respiratory system as well as 
producing stronger skeletal muscle. If this is the case, these changes might have also 
produced the improvements in motor function and survival. 
There are several limitations in our studies. First, the half-life of CyPPA is 
unknown. Pharmacokinetic data as well as a dose response curve would have 
ensured proper dosing of the drug and potentially more favorable outcomes from 
these experiments. Without this pharmacokinetic data, choosing a concentration 
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which could produce therapeutic effects was just based on concentrations in 
literature. A concentration of 14mg/kg was settled upon and we did see significant 
effects. It is possible that far greater benefits could have been produced if an optimal 
dosage was obtained. Improvements in motor function were found at this 
concentration in the 16 day treatment of CyPPA commencing at P5 and the 7 day 
treatments of CyPPA starting at P90. Moreover, the 16 day neonatal treatments of 
CyPPA also prolonged survival in our SOD1 mutants. The presence of 
pharmacokinetic data would have guided our efforts in selecting an optimal dosing 
concentration. Even though CyPPA produced therapeutic effects we are unsure 
whether these effects are mediated via SK channels on MNs . SK channels are found 
in numerous cell types. Our lab currently has ongoing experiments to test whether 
CyPPA effects are mediated through MNs. Published data support the idea of CyPPA 
as a therapy for glutamate-induced excitotoxicity (Dolga et al 2008) and there is 
evidence showing that treatment with CyPPA could improve motor function in other 
neurodegenerative diseases which share similarities to ALS (Benítez et al 2011). 
Another limitation arose during the Riluzole study. Gurney et al 1998 
suggested the optimal dosage for Riluzole in adults SOD1 mutants should be 
44mg/kg. Initially we started with this concentration for our neonatal injections but 
we were met with complications. 44mg/kg was too high of a concentration for pups 
and several of the animals did not survive the treatment. The concentration was 
then dropped to 33mg/kg and pups were still being lost. Finally, at a concentration 
of 22mg/kg, half of the optimal dosage in adults, pups were able to survive the full 
16 day dosing period.  
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For future studies it would be imperative to test other SK channel activators 
to ensure the beneficial effects are not limited to one drug. Conversely, instead of 
testing SK channel activators it would be interesting to test an SK channel blocker as 
well. Apamin, a neurotoxin found in bee venom selectively blocks SK channels, 
eliminating the mAHP and increasing cell firing rate (Castle, Haylett, & Jenkinson, 
1989; Herrik et al., 2012). It would be interesting to see if ALS symptoms become 
exacerbated when SK channels become blocked and if our SOD1 mutants become 
symptomatic earlier. 
There have been some criticisms about the G93A-H transgenic line. Using a 
transgenic line with that has longer disease progression such as the G93A-L or the 
G85R lines might increase the understanding of disease mechanism and could 
potentially provide insight into other pathologies which might become altered. 
Finally, the search for early diagnosis has been an ongoing struggle in this field. 
Using various techniques, such as nerve conduction studies, electrical impedance 
myography (EIM), Dual-energy X-ray absorptiometry (DEXA) ( which measures lean 
body mass), ultrasound, histology or electrophysiology may uncover novel 
biomarkers. Enabling early diagnosis and allowing patients to receive treatments in 
a timely manner, before symptoms become too severe. 
In conclusion drug administration with CyPPA produced significant 
improvements in both motor function and survival. Short teom neonatal drug 
administration and short term drug administration during symptom onset proved 
to be most beneficial suggesting that activation of SK channels via CyPPA can 
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produce therapeutic effects and that SK channels are indeed viable drug targets. 
Another interesting outcome from this study was that neonatal treatment with 
Riluzole did not have an impact on survival or motor function while CyPPA did. This 
suggests that neonatal interventions with Riluzole are not beneficial but more 
importantly that channel specificity could be required for therapeutic effectiveness. 
Perhaps the most encouraging fact about this drug is that it has been previously 
shown to improve motor function in other neurodegenerative diseases such as SCA2 
and SMA (Dimitriadi et al., 2013; Kasumu et al., 2012). While CyPPA is not yet FDA 
approved, positive results like these suggest that in time CyPPA may become a 
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